Global X Longevity Thematic ETF LNGR 深 滬
已收盤 03-31 16:00:00 美东时间
27.75
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 27.75
- 總市值 4023.20万
- 52周最高 28.5131
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 18.8472
- 委 比 0.00%
- 總股本 144.98万
- 歷史最高 28.5131
- 量 比 0
- 振 幅 0.00%
- 歷史最低 13.0547
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
Longeveron announced the full enrollment of its pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential treatment for hypoplastic left heart syndrome (HLHS), a rare and severe congenital heart defect. ELPIS II is expected to release top-line results in the third quarter of 2026, following encouraging outcomes from the Phase 1 trial, which showed 100% transplant-free survival in treated patients up to age five. The thera...
10-27 13:15
